The University of Southampton
Warning! Your browser is out-of-date and not compatible with this website. Please download a new secure and faster browser to view this website correctly.
News and events

Getting antibodies into shape to fight cancer

Published: 
12 December 2014

Scientists at the University of Southampton have found that the precise shape of an antibody makes a big difference to how it can stimulate the body's immune system to fight cancer, paving the way for much more effective treatments.

The latest types of treatment for cancer are designed to switch on the immune system, allowing the patient’s own immune cells to attack and kill cancerous cells, when normally the immune cells would lie dormant.

In a study, funded by Cancer Research UK and published in the journal Cancer Cell, the Southampton team have found that a particular form of antibody, called IgG2B, is much more effective at stimulating cancer immunity than other types. Unlike other forms of antibody, IgG2B can work independently without needing help from other immune cells, making it more active and able to work in all tissues of the body. The team have also been able to engineer antibodies that will be locked into the particular shape (called a locked B structure) that is most active, making them much stronger immune stimulators than previous drugs.

Dr Ann White, who led the study, comments: “We know that the immune system provides a natural protection against cancer, which can only grow by finding a way around our defences. Antibody treatments are now able to correct this problem for many types of cancer, but we still need them to work better.

“It is early days, but this important discovery could enable us to treat more cancers effectively. Our next task is to bring these novel IgG2B antibodies into trials for cancer patients and we are engineering ways to make them effective in the clinic.”

The team is now working to discover why the IgG2 molecule works better in a locked B structure. To do this the molecule has been crystallised and an x-ray shone through it so the structure can be assessed. It is the first time that the IgG2 has been crystallised.

Professor Nic Jones, Cancer Research UK’s chief scientist, said: “This research has zeroed in on how we can make immunotherapy treatments more effective against cancer. Energising the immune cells in our body and getting them to treat cancer cells as a threat gives us a better shot at beating cancer. Immunotherapy is part of the future of cancer treatment and it’s important that we use our best immunotherapy weapons to fight the disease.”

This latest work is one example of a wide ranging research programme into cancer immunotherapy at the University of Southampton. The team runs clinical trials and has had notable success with immunotherapy in the treatment of hard to beat cancers, specifically: skin, lung, lymphoma and pancreatic cancer, as well as the childhood cancer, neuroblastoma. The University is currently raising £20million to build a new dedicated cancer immunology research centre, which is anticipated to be open in 2016. To find out more about the campaign visit www.southampton.ac.uk/cancerimmunology

 

Share this articleFacebookGoogle+TwitterWeibo

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×